Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
161 studies found for:    "juvenile idiopathic arthritis" OR "Arthritis, Juvenile Rheumatoid"
Show Display Options
Rank Status Study
21 Completed 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy
Condition: Juvenile Idiopathic Arthritis
Intervention: Biological: anti-TNF
22 Terminated An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Givinostat
23 Completed Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: methotrexate prefilled pen
24 Terminated
Has Results
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
Condition: Systemic Juvenile Idiopathic Arthritis
Interventions: Drug: Canakinumab;   Drug: Placebo
25 Unknown  Magnetic Resonance Imaging Follow-up on Temporomandibular Arthritis in Children With Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Procedure: Steroid injection into the TMJs.
26 Recruiting A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Tocilizumab
27 Terminated
Has Results
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: RoActemra/Actemra (tocilizumab)
28 Completed
Has Results
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: Tocilizumab;   Drug: Placebo
29 Completed
Has Results
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra];   Drug: Placebo;   Drug: Non-steroidal anti-inflammatory drugs (NSAIDs);   Drug: methotrexate;   Drug: corticosteroids
30 Completed A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
31 Recruiting Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Tocilizumab
32 Completed
Has Results
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
33 Completed
Has Results
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
34 Completed An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
35 Withdrawn An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Condition: Systemic Juvenile Idiopathic Arthritis
Interventions: Drug: ACZ885;   Drug: Canakinumab
36 Recruiting An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Sarilumab SAR153191 (REGN88)
37 Active, not recruiting Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Abatacept
38 Completed An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: Canakinumab
39 Completed Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
Condition: Systemic-Onset Juvenile Idiopathic Arthritis
Interventions: Drug: Anakinra;   Biological: Pneumo23
40 Active, not recruiting a Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis Who Participated in the Study CACZ885G2301E1
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: canakinumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.